Physician profile
Ren Bernardo
NPI 1639304389
$405.50
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $59.22 · 2021: $39.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $70.17 | 2019-2020 | |
| Nevro Corp. | $63.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $61.43 | 2019-2020 | |
| Amgen INC. | $54.82 | 2019 | |
| Abbvie INC. | $38.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $27.32 | 2019-2021 | |
| Lilly USA, LLC | $24.35 | 2019-2020 | |
| Abbott Laboratories | $15.17 | 2019 | |
| Astellas Pharma US INC | $14.86 | 2019 | |
| Novo Nordisk INC | $12.00 | 2019 | |
| Horizon Therapeutics Plc | $11.54 | 2019 | |
| Pfizer INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ren Bernardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.